ClinicalTrials.gg
RecruitingNCT06469970INDICIAUpdated Mar 12, 2026

Evolution of the Initial Distribution Volume of Glucose in the Severe Burned Adults

A Phase 2 interventional study of Glucose 30% Intravenous Solution in Burns, Intensive Care and Emergencies, sponsored by Centre Hospitalier Régional Metz-Thionville. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Centre Hospitalier Régional Metz-Thionville · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Burns with a site in France — 6 open to participants now, 7 under way, 2 of them phase 3. Burns · France.

Planned enrollment
17th of 22
15 · median 27
Started
2024
with 1 other
Phase 2
3 of 32
1 open now
Registered
27th of 32
by date
Lead sponsor
2 of 32
Centre Hospitalier Régional Metz-Thionville

Among the 32 studies in Burns with a site in France, this one is the 17th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 2, and was the 27th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

6 of the 32 studies in Burns with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Burns with a site in France, or all of them as a file.
02

Study summary

This is a prospective, observational, monocentric, phase II (exploratory) cohort study aiming to describe the evolutionary profile of the initial volume of glucose distribution (IDVG) during the first four days of management of severely burned patient.

Read the detailed description

In the early phase, severe burns induce a state of hypovolaemic shock linked to inflammation and a capillary leak syndrome, responsible for the formation of a voluminous third sector. Initial resuscitation of burn patients is based on an assessment of filling requirements using the Parkland formula, which takes into account the patient's weight and the percentage of burned skin surface. This haemodynamic resuscitation oscillates between a risk of underfilling, responsible for hypovolaemia with low cardiac output and leading to excess mortality, and a state of hydric hyperinflation responsible for numerous complications such as respiratory distress, cardiac failure, abdominal compartment syndrome, and even excess mortality. The necessary adaptation of vascular filling rates is usually achieved by monitoring clinical parameters such as diuresis, or biological parameters such as arterial lactate or haematocrit. More advanced haemodynamic monitoring may be applied in addition, but the targets chosen and their numerical objectives remain to be validated. Due to the burn-induced capillary leak syndrome, quantification of extracellular (intra- and extravascular) fluid volume (ECFV) could be a relevant marker of fluid overload status in severely burned patients. ECFV can be estimated using intravenous glucose. Glucose is distributed throughout the extracellular fluid compartment within a few minutes, and defines an initial volume of glucose distribution (IDVG) proportional to the ECFV. This measurement has been validated in healthy individuals and in various pathological conditions. In intensive care patients, the values are between 3.1 and 4.8 L/m2.

To the best of our knowledge, no study has assessed variations in ECV measured by the LVDI in severely burned patients in the early phase of intensive care. Understanding these variations could make a definite contribution to the adaptation of perfused fluid volumes.

03

Conditions studied

  • Burns
  • Intensive Care
  • Emergencies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years of age
  • Patients hospitalized with burns of at least 30% of body surface area

    • By a thermal mechanism
    • At the CHR Metz-Thionville burn center
    • managed within the 8 hours post-burn
  • Patient affiliated to a social security scheme
  • Written consent obtained from the patient (or from the trusted person, family or relatives if the patient is unable to sign/express consent) or emergency inclusion if the patient is unable to express consent and neither the trusted support person nor any member of the family or relatives is present at the time of inclusion.

Exclusion criteria

Exclusion Criteria:

  • Diabetic patients on insulin
  • Patient with a to GLUCOSE 30% PROAMP, solution for injection
  • Patients with pre-hospital cardiac arrest
  • extra corporeal circulation patient: Extra Corporeal Membranous Oxygenation (ECMO) or Extra Corporeal Life Support (ECLS) or CRRT (Continuous Renal Replacement Therapy)
  • patient without a central venous line or arterial catheter
  • Patient moribund or immediately subject to therapeutic limitation
  • Impossibility of trans-pulmonary thermodilution monitoring (vascular access difficulties)
  • Pregnant, parturient or breast-feeding women
  • Patient under guardianship, curatorship or safeguard of justice
  • Cognitive impairment or language barrier
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Glucose administration

    Drug: Glucose 30% Intravenous Solution

Interventions

  • DrugGlucoseStudies of GlucoseGlucose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Measurement of IDVG on admission, at 4 hours (H+4), and at 8, 16, 24, 48, 72 and 96 hours (H+8, H+16, H+24, H+48, H+72 and H+96) post-burn. The principle of this measurement consists of taking a reference blood glucose level measured on an arterial blood sample (arterial catheter) using a blood glucose meter. A bolus of 5g of glucose is injected into a central venous line over 30 seconds. A second blood glucose level is measured 3 minutes after the end of the injection. The intra-thoracic blood volume (ITBV) and extra-vascular lung water (EVLW) are measured using the PiCCO device as part of the usual management of burn patients.

06

What researchers measure

Primary outcomes

  1. Description of the mean values of the initial volume of glucose distribution (IDVG)

    The IDVG is calculated according to the method described by Hitota et al. A reference blood glucose level is measured on an arterial blood sample (arterial catheter) by a blood glucose meter. A bolus of 5 g of glucose is injected into a central venous line over 30 seconds. A second blood glucose level is measured 3 minutes after the end of the injection. The difference between the two blood glucose levels is recorded as d\[glu\] in mg/dl. IDVG = 24.4 x e(-0.0298 \* d\[glu\]) + 2.7 in liters

    Time frame: on admission, at Hours 4, 8, 16, 24, 48, 72 and 96 post-burn

Secondary outcomes

  1. Study of correlations between initial distribution volume of glucose (IDVG), intra-thoracic blood volume (ITBV) and extra-vascular lung water (EVLW).

    ITBV (intra-thoracic blood volume) and EVLW (extra-vascular lung water) measured at the same time as IDVG, using the PiCCO device and trans-lung dilution of a thermal indicator (cold saline).

    Time frame: on admission, at Hours 4, 8, 16, 24, 48, 72 and 96 post-burn

  2. Study of correlations between IDVG and body surface area (BSA)

    Body surface area assessed on admission according to Wallace method

    Time frame: at hospital admission

  3. Study of correlations between IDVG and water intake and input/output balance

    Water intake and input/output balance (water intake minus diuresis)

    Time frame: on admission, at Hours 4, 8, 16, 24, 48, 72 and 96 post-burn

  4. Study of correlations between IDVG at H24 to H48 and mortality

    In-hospital mortality

    Time frame: at Hours 24 and 48 post-burn

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.

Of 17 phase 2 interventional studies under Burns, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 61. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2024
First posted
Jun 24, 2024
StartActual
Nov 28, 2024
Primary completionEst.
Mar 28, 2027
CompletionEst.
Mar 28, 2027
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06469970
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Nov 28, 2024
Primary completion
Mar 28, 2027 (estimated)
Completion
Mar 28, 2027 (estimated)
Last update
Mar 12, 2026

Study contacts

Arpiné EL NAR, PhD
Contact
projet-recherche-clinique@chr-metz-thionville.fr
0033387557766
Serge LE TACON, MD
principal investigator · CHR Metz Thionville Hopital de Mercy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glucose

Start the discussion